TGA
- Status: likely_approved
🇦🇺 Hu3F8 in Australia
Hu3F8 (NAXITAMAB) regulatory status in Australia.
Marketing authorisation
Hu3F8 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Australia
Frequently asked questions
Is Hu3F8 approved in Australia?
Yes. TGA has authorised it.
Who is the marketing authorisation holder for Hu3F8 in Australia?
Y-Mabs Therapeutics Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.